

Table 2. Listing of HCV Variants With Proposed Changes in Genotype Nomenclature

Proposed Designation*	Published Designation	Status†	Isolate‡	Region Sequenced§	Reference(s)
Genotype 2					
2k	2j	C	RU169	NS5B (D86532), 3'UTR (D86532)	83
2j	2l	P	BA047	NS5B (D86530), 3'UTR (D86530)	83
2n	2e	P	NL50	C/E1 (L39309), NS5B (L44602)	84
2o	4f/2f	P	FR4	C/E1 (L38333), NS5B (L38373)	84
2p	2f	P	NL33	C/E1, (L39300), BS5B (L44601)	84
2q	2k	P	BA045	NS5B (D86529), 3'UTR (D86529)	83
Genotype 3					
3k	10a	C	HPCJK049E1	Complete genome (D63821)	59
Genotype 4					
4r	4a	P	Z4	C/E1 (U10236/L16652)	12, 64
			FrSSD120	C/E1 (AJ401097), NS5B (AJ291282)	93
4n	4 alfa	P	1359	C/E1 (AF271874)	65
4o	4 beta	P	2153	C/E1 (AF271882), NS5B (AF271815)	65
Genotype 6					
6c	7d	P	Th846	C/E1 (D37843), NS5B (D37857)	35
6d	7b	C	VN235	Complete genome (D84263)	83
6e	7a	P	VN540	C/E1 (D88474), NS5B (D87361)	34
6f	7e	P	BB7	NS5B (D28541)	96
6f	7c	P	Th271	C/E1 (D37844), NS5B (D37858)	35
6g	11a	C	HPCJK046E	Complete genome (D63822)	59
6h	9a	C	VN004	Complete genome (D84265)	83
6i	9b	P	Th555	C/E1 (D37849), NS5B (D37863)	35
6j	9c	P	Th553	C/E1 (D37848), NS5B (D37862)	35
6k	8b	C	VN405	Complete genome (D84264)	34
6l	8a	P	VN507	C/E1 (D88470), NS5B (D87357)	34

*Proposed new name based on revised criteria for genotype designations.

†Classification status; C: Confirmed; P: Provisional.

‡Example of isolates referred to in associated publications (last column).

§Regions sequenced (accession numbers in parentheses), prioritized for (1) complete genome; (2) Core/E1 and NS5B regions; (3) other regions where core/E1 and NS5B regions are not both available.

- The genetic groups will be termed "genotypes." The previously proposed term "clade" to describe an HCV genotype might be regarded as an alternative, more descriptive term for genotype, and is currently used in the VIIIth ICTV Report.¹ However, for consistency with previous classifications of HCV and current clinical usage, we recommend the use of the term "genotype" for genetic group in HCV sequence databases and publications.
- Variants of HCV currently designated with genotype numbers above 6 will be renamed according to the genotype group in which they fall, and with the next available subtype designation (Table 2). For example, genotype 10a will be re-classified as 3k, 7a as 6e, and so forth. The proposed changes to the nomenclature are presented in Table 2.
- The identification of new genotypes will henceforth require demonstration of a consistent independent phylogenetic grouping away from any of the currently classified genotypes of HCV (see later discussion).

Classification and Nomenclature of Previously Described Subtypes of HCV. The group believed the exist-

ing nomenclature of HCV genotypes and subtypes provided a valuable framework for ongoing studies of genetic variation. The following points summarize the group's decisions and recommendations for subtype designations:

- Existing designations where they are consistent will be retained, irrespective of the criteria agreed for the designation of new subtypes (Tables 1 and 3).
- Variants within genotypes 3 and 6 that have been re-designated as subtypes (see previous section) will be incorporated into the updated list.
- HCV variants with conflicting names in the literature have been re-designated on consultation with the originating authors (Table 2).

Assignment of New Genotypes of HCV. Further variants of HCV likely will be discovered that merit their assignment as new genotypes, such as the candidate new genotype obtained from Central Africa.^{61,62} To ensure their correct classification, it is essential to demonstrate that there is no significant grouping within any of the existing genotypes. This has to be demonstrated by rigorous phylogenetic analysis of a complete sequence of the coding region of the virus. This analysis will additionally

Table 3. Provisionally Assigned HCV Subtypes

	Isolate†	Accession Number(s)*		Reference(s)
		Core/E1	NS5B	
Genotype 1				
1d	HC1-N15, HC1-N16	L39299, L39302	L38377, L38372	84
1e	CAM1078, QC248	L38349(C), AY894555	L38361, AY894553	62, 84
1f	FR2	L38350	L38371	84
1g	2152, 1382	AF271822, AF271820	AF271798, AF271797	65
1h	98CM1521, QC94	AY256790(C), AY434131	AY257087, AY434132	32, 62
1i	FR16, QC77	n.a., AY434119	L48495, AY434120	62, 85
1j	QC2, QC89	AY434158, AY434128	AY434106, AY434129	62
1k	QC68, QC82	AY434112, AY434122	AY434113, AY434123	62
1l	98CM1383, 98CM1427	AY256789(C), AY256792(C)	AY257083, AY257091	32
Genotype 2				
2d	NE92, BN177	L39294, n.a.	L29634, AF037244	66, 86
2e	JK020, JK025	D49745, D49746	D49760, D49761	59
2f	JK081, JK139	D49754, D49757	D49769, D49777	59
2g	MED017	n.a.	X93323	26
2h	MED007	n.a.	X93327	26
2i	FR13, HN4	n.a., X76411/X76415	L48492, L48499	87, 88
2j	BA047, QC106	n.a., AY894528	D86530, AY894526	62, 83
2l	FR15	n.a.	L48494	85, 89
2m	QC76, QC104	AY434116, AY434143	AY434117, AY434144	62
2n	NL50	L39309	L44602	84
2o	FR4	L38333	L38373	84
2p	NL33	L39300	L44601	84
2q	BA045	n.a.	D86529	83
Genotype 3				
3c	NE048	D16612	D14198/D16613	33
3d	NE274	D16620	D14200/D16621	33
3e	NE145	D16618	D16619	33
3f	NE125, PK64	D16614, n.a.	D14203/D16615, L78842	33, 87
3g	IND1751, IND1452	X91423/X91307, X91306(C)	X91417, X91418	90
3h	QC29, SOM1	U33437(C), AF216792/AF216786	AF279120, AF216789	91, 92
3i	IND674, QC100	X91300(C), AY434137	X91422, AY434138	62, 90
Genotype 4				
4b	Z1	U10235/L16677	n.a.	12, 64
4c	Z6, GB358	U10238/L16678, L29606	n.a., L29607	12, 64, 66
4d	DK13, SD006	U10192/L16656, n.a.	n.a., D86537	12, 64, 83
4e	CAM600, GB809	L29589, L29629	L29590, L29626	66
4f	G22, FR12	L29595, L38332	L29593, L38370	66, 84
4g	GB549	L29620	L29621	66
4h	GB438, FrSSD35	L29610, n.a.	L29611, AJ291249	66, 93
4i	CAR4/1205	L36439	L36437	28
4j	CAR1/501	n.a.	L36438	28
4k	B14, FrSSD174	L39282, n.a.	L44597, AJ291294	84, 93
4l	SD002, 2116	n.a., AF271881	D86534, AF271816	65, 83
4m	SD035, 1797	n.a., AF271876	D86543, AF271813	65, 83
4n	1359, QC97	AF271874, AY434134	n.a., AY434135	62, 65
4o	2153, QC59	AF271882, AY434107	AF271815, AY434108	62, 65
4p	FrSSD158, QC139	AJ401099(E), AY434149	AJ291285, AY434150	62, 93
4q	QC86, QC107	AY434125, AY434146	AY434126, AY434147	62
4r	Z4, FrSSD120	U10236/L16652, AJ401097(E)	n.a., AJ291282	12, 64, 93
4t	98CM1458, QC85	AY256808(C), AY706996	AY257072, AY706997	32, 62
Genotype 6				
6c	Th846	D37843	D37857	35
6e	VN540, VN998	D88474, D31971	D87361, D30797	34
6f	Th271, EUTH36	D37844, U31261(C)	D37858, U31276	24, 35
6i	Th555, EUTH100	D37849, L50554(C)	D37863, L50535	35, 94
6j	Th553, EUTH1	D37848, L49473(C)	D37862, L49481	35, 56
6l	VN507, VN531	D88470, D88472	D87357, D87359	34
6m	EUBUR1, B4/92	L49480(C), D63943/D63944	L49484, D28543	56, 95
6n	D86/93, EUTH86	D63945, U31259(C)	D28545, U31275	24, 96
6o	VN4, QC33	L38341, AY894537	L38382, AY894535	62, 84
6p	VN12, QC123	L38340, AY894534	L38380, AY894532	62, 84
6q	QC57, QC176	AY754632, AY754617	AY754633, AY754618	62

*Accession numbers of sequences from the core/E1 and NS5B regions. Where two examples are listed, a comma divides the accession numbers from the two entries; "n.a.": not available; "/": denotes that the core/E1 or NS5B sequences are available from two different accession numbers; (C): only core sequence available; (E): only E1 sequence available.

†Listing of up to two examples of each provisionally assigned HCV subtype prioritized according to (1) availability of complete or near complete core/E1 and NS5B sequences, (2) publication date, (3) GenBank/EMBL/DBJ submission date. Where possible, the isolate names referred to in associated publications (last column) are listed for ease of reference.

confirm the absence of recombination with sequences from other genotypes.

The following criteria were proposed for identification and designation of a variant of HCV as a new genotype:

1. *Provisional designation.* This requires one complete coding region sequence to be obtained, the demonstration of a separate grouping from other genotypes by phylogenetic analysis, and an absence of recombination. The sequence of a candidate new genotype should be independently analyzed by submission to one of the HCV databases. The sequence will be analyzed by a variety of phylogenetic methods described previously. This will allow the sequence to be assigned with the next available genotype number, and the subtype designation "a," for example, genotype 7a.
2. *Confirmed designation.* This requires coding sequences of 2 or more HCV variants from infections that are not directly linked epidemiologically. The sequences should further demonstrate a lack of grouping with current classified genotypes by the above methods. This further analysis, and any available sequences from subgenomic regions such as core/E1 and NS5B (see later discussion), will provide valuable reference information on the genetic heterogeneity within the newly designated genotype, the existence of subtypes, the geographical origins of the variants, and their likely designation in 5'UTR-based genotyping assays.

Assignment of New Subtypes of HCV. Different issues apply to the assignment of new subtypes. Some geographical regions contain so much diversity within genotypes that it is of little value to continue classifying them as subtypes. Elsewhere, however, subtype labels have particular epidemiological value and are widely used as genetic markers in studies of past and ongoing virus transmission of HCV in different risk groups.

To recognize this distinction, new subtype designations should only be provided where there is evidence for its spread in particular transmission networks, and where its identification would be of epidemiological value. The simplest method to achieve this distinction is to require evidence of infection with a new proposed subtype of HCV in several independently infected individuals.

The following criteria for assignment of new subtypes were proposed:

Provisional designation. Three or more examples of infection with a new proposed subtype are required for subtype designation. Sequences are required from both the core/E1 region (sequence data available from 90% or more nucleotides corresponding to positions 869 to 1292

in the H77 reference sequences, accession number AF009606)^{12,63-65} and the NS5B region (data from 90% or more positions in the region 8276-8615 in H77).^{7,8,66} The sequences of primers suitable for amplification of these regions from a wide range of HCV genotypes will be made available on the public databases.

Sequences will be analyzed by a variety of distance-based, parsimony, and maximum likelihood methods, and evidence sought for consistent phylogenetic grouping together and distinctness from other subtypes. Because currently classified subtypes of HCV differ in nucleotide sequence from each other by more than 15%, at least this level of divergence will be expected from other HCV variants within the genotype. However, as described in the Introduction, the existence of separately identifiable subtypes is primarily an epidemiological phenomenon associated with its recent spread. Because subtype designation are primarily epidemiological labels, it is clearly not appropriate or of value to develop formal criteria for their assignment. Indeed, the varying degrees of sequence divergence of variants within different genotypes would make the development of such criteria extremely difficult.

Candidate subtypes will be provisionally assigned with the next available subtype letter for the genotype on submission to one of the HCV databases. Sequences from the 5'UTR will be of value for assessment of their appearance in commonly used genotyping assays but are not required. Single or pairs of variants of HCV that would otherwise be designated as new subtypes by these criteria will not be assigned a subtype letter in the database.

Confirmed designation. One or more complete genome sequences will be required for confirmed designation. This will allow the degree of sequence divergence from other subtypes over the whole genome to be assessed as well as confirming an absence of recombination.

Assignment of Recombinant Forms of HCV. It is important that the classification scheme for HCV genotypes should be able to incorporate HCV recombinants. However, with the current description of only 2 or 3 confirmed or possible recombinants in the literature, it was deemed to be of less immediate importance to classify these formally, and to develop rules for nomenclature. Until review at a subsequent classification meeting, sequences with evidence of recombination will be annotated as such in the databases, with options to include or exclude them from downloads or analyses of sequences.

Interface With HCV Sequence Databases. The HCV sequence databases are in a unique position to support the effort to make the HCV nomenclature more uniform. By assigning geno/subtypes to the sequences that people retrieve and download, they can influence the

commonly used nomenclature of existing sequences, whereas they can have a coordinating role in assigning new geno/subtypes and keeping track of these, especially before journal publication. The databases are also committed to assist in the naming of new geno/subtypes, through helping researchers name proposed new geno/subtypes, by checking existing names for consistency and correcting any inconsistencies that are found, by making it easy for the field to keep track of which geno/subtype names have already been assigned, and by providing tools for genotype or subtype identification and detecting recombinants.

The HCV database websites will provide access to the criteria for assignment of new genotypes and subtypes of HCV developed in this consensus paper, and make HCV researchers, reviewers, and journal editors aware of these guidelines. They will provide the listing of current assigned subtypes and genotypes (based on Tables 1 and 3), but will be automatically updated as sequence data are submitted, showing which designations exist in the databases, but not those that have been given out and not yet published. The distinction between "provisional" and "confirmed" designations will also be implemented in the databases through the provision of a separate field for this category. The genotype name re-assignments in Table 2 will similarly be made available, and the 3 databases will keep in continuous contact to ensure that the nomenclature of currently existing sequences is uniform and free of conflicts.

Summary

This report describes a series of proposals for the classification of HCV variants into genotypes and subtypes. It addresses both current problems with the nomenclature of existing variants, and incorporates our improved understanding of the genetic diversity and epidemiology of HCV into the revised criteria for the designation of new genotypes and subtypes. The consensus meeting provided the opportunity to compile for the first time a full listing of currently described variants of HCV (Tables 1 and 3), and the opportunity to perform the minimum number of genotype and subtype name re-assignments to create consistency in nomenclature (Table 2).

Finally, these proposals serve as a framework for access to the 3 databases, which will follow the revised nomenclature presented here for sequence retrieval, and to use the revised criteria for classification in their coordinating role in the assignment of new genotypes and subtypes; this will be of major value in preventing future inconsistencies in nomenclature.

References

1. Thiel HJ, Collett MS, Gould EA, Heinz FX, Houghton M, Meyers G, et al. Flaviviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. *Virus Taxonomy*, VIIIth Report of the ICTV. 2005:979-996.
2. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. *Arch Virol* 1998;143:2493-2503.
3. Combet C, Penin F, Geourjon C, Deleage G. HCVDB: Hepatitis C virus sequences database. *Appl Bioinformatics* 2004;3:237-240.
4. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. *Bioinformatics* 2005;21:379-384.
5. Cha TA, Beall E, Irvine B, Kolberg J, Chien D, Kuo G, et al. At least five related, but distinct, hepatitis C viral genotypes exist. *Proc Natl Acad Sci U S A* 1992;89:7144-7148.
6. Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follett E, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. *J Gen Virol* 1992;73:1131-1141.
7. Simmonds P, Holmes EC, Cha TA, Chan S-W, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol* 1993;74:2391-2399.
8. Enomoto N, Takada A, Nakao T, Date T. There are two major types of hepatitis C virus in Japan. *Biochem Biophys Res Commun* 1990;170:1021-1025.
9. Okamoto H, Kurai K, Okada S, Yamamoto K, Lizuka H, Tanaka T, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. *Virology* 1992;188:331-341.
10. Mori S, Kato N, Yagyu A, Tanaka T, Ikeda Y, Petchelai B, et al. A new type of hepatitis C virus in patients in Thailand. *Biochem Biophys Res Commun* 1992;183:334-342.
11. Tsukiyama Kohara K, Kohara M, Yamaguchi K, Maki N, Toyoshima A, Miki K, et al. A second group of hepatitis C viruses. *Virus Genes* 1991;5:243-254.
12. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. *Proc Natl Acad Sci U S A* 1993;90:8234-8238.
13. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. *HEPATOLOGY* 1994;19:1321-1324.
14. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. *J Gen Virol* 1994;75:1053-1061.
15. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. *Virology* 1991;180:842-848.
16. Kato N, Ootsuyama Y, Ohkoshi S, Nakazawa T, Sekiya H, Hijikata M, et al. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. *Biochem Biophys Res Commun* 1992;189:119-127.
17. Kumar U, Brown J, Monjardino J, Thomas HC. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. *J Infect Dis* 1993;167:726-730.
18. Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T, et al. A structurally flexible and antigenically variable n-terminal domain of the hepatitis C virus e2/NS1 protein: implication for an escape from antibody. *Virology* 1993;195:297-301.
19. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. *Proc Natl Acad Sci U S A* 1992;89:3468-3472.
20. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasi-species. *Science* 2000;288:339-344.

21. Kantzanou M, Lucas M, Barnes E, Komatsu H, Dusheiko G, Ward S, et al. Viral escape and T cell exhaustion in hepatitis C virus infection analysed using class I peptide tetramers. *Immunol Lett* 2003;85:165-171.
22. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. *J Virol* 2001;75:5703-5710.
23. Jeannel D, Fretz C, Traore Y, Kohdjo N, Bigot A, Gamy EP, et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. *J Med Virol* 1998;55:92-97.
24. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P, International Collaborators. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. *J Gen Virol* 1995;76:2493-2507.
25. Wansbrough Jones MH, Frimpong E, Cant B, Harris K, Evans MRW, Teo CG. Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. *Trans R Soc Trop Med Hyg* 1998;92:496-499.
26. Ruggieri A, Argentini C, Kouruma F, Chionne P, D'Ugo E, Spada E, et al. Heterogeneity of hepatitis C virus genotype 2 variants in West Central Africa (Guinea Conakry). *J Gen Virol* 1996;77:2073-2076.
27. Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. *J Virol* 2003;77:7914-7923.
28. Fretz C, Jeannel D, Stuyver L, Herve V, Lunel F, Boudifa A, et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. *J Med Virol* 1995;47:435-437.
29. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborcht B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. *J Gen Virol* 1993;74:1093-1102.
30. Menendez C, Sanchezzapatas JM, Alonso PL, Gimenez Barcons M, Kahigwa E, Apante JJ, et al. Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. *J Clin Microbiol* 1999;37:2333-2336.
31. Xu LZ, Larzul D, Delaporte E, Brechot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). *J Gen Virol* 1994;75:2393-2398.
32. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. *J Gen Virol* 2003;84:2333-2341.
33. Tokita H, Shrestha SM, Okamoto H, Sakamoto M, Hirokita M, Iizuka H, et al. Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. *J Gen Virol* 1994;75:931-936.
34. Tokita H, Okamoto H, Tsuda F, Song P, Nakata S, Chosa T, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. *Proc Natl Acad Sci U S A* 1994;91:11022-11026.
35. Tokita H, Okamoto H, Luengrojankul P, Vareesangthip K, Chainuvati T, Iizuka H, et al. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. *J Gen Virol* 1995;76:2329-2335.
36. Simmonds P. 2000 Fleming Lecture. The origin and evolution of hepatitis viruses in humans. *J Gen Virol* 2001;82:693-712.
37. Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. *J Infect Dis* 2002;186:1212-1221.
38. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behaviour of hepatitis C virus. *Science* 2001;22:2323-2325.
39. Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a bayesian coalescent approach. *Mol Biol Evol* 2003;20:381-387.
40. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. *J Virol* 2002;76:4034-4043.
41. Kalinina O, Norder H, Magnius LO. Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. *J Gen Virol* 2004;85:1853-1857.
42. Colina R, Casane D, Vasquez S, Garcia-Aguirre L, Chunga A, Romero H, et al. Evidence of intratypic recombination in natural populations of hepatitis C virus. *J Gen Virol* 2004;85:31-37.
43. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. *Antivir Ther* 2005;10:1-11.
44. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborcht B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. *J Gen Virol* 1993;74:1093-1102.
45. Maertens G, Stuyver L. HCV genotyping by the line probe assay INNO-LiPA HCV II. In: Lau JYN, ed. *Hepatitis C Protocols*. Totawa: Human Press, 1998:183-198.
46. McOmish F, Chan S-W, Dow BC, Gillon J, Frame WD, Crawford RJ, et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serological reactivity and rate of alanine aminotransferase abnormalities. *Transfusion* 1993;33:7-13.
47. Davidson F, Simmonds P. Determination of HCV genotypes by RFLP. In: Lau JYN, ed. *Hepatitis C Protocols*. Totawa: Human Press, 1998:175-181.
48. Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. *J Clin Microbiol* 2000;38:3581-3584.
49. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV type 1, type 2, and type 3. *J Clin Microbiol* 1993;31:1493-1503.
50. Tanaka T, Tsukiyamachara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. *HEPATOLOGY* 1994;19:1347-1353.
51. Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. *J Infect Dis* 1995;171:281-289.
52. Bhattacharjee V, Prescott LE, Pike I, Rodgers B, Bell H, Elzayadi AR, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. *J Gen Virol* 1995;76:1737-1748.
53. Zheng X, Pang M, Chan A, Roberto A, Warner D, Yen-Lieberman B. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. *J Clin Virol* 2003;28:214-216.
54. Gault E, Soussan P, Morice Y, Sanders L, Berrada A, Rogers B, et al. Evaluation of a new serotyping assay for detection of anti-hepatitis C virus type-specific antibodies in serum samples. *J Clin Microbiol* 2003;41:2084-2087.
55. Dansako H, Naganuma A, Nakamura T, Ikeda F, Nozaki A, Kato N. Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. *Virus Res* 2003;97:17-30.
56. Mellor J, Walsh EA, Prescott LE, Jarvis LM, Davidson F, Yap PL, et al. Survey of type 6 group variants of hepatitis C virus in southeast Asia by using a core-based genotyping assay. *J Clin Microbiol* 1996;34:417-423.
57. Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, et al. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. *J Gen Virol* 1995;76:1749-1761.
58. Samokhvalov EI, Hijikata M, Gylka RI, Lvov DK, Mishiro S. Full-genome nucleotide sequence of a hepatitis C virus variant (isolate name VAT96) representing a new subtype within the genotype 2 (arbitrarily 2k). *Virus Genes* 2000;20:183-187.
59. Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Lesmana LA, et al. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. *J Gen Virol* 1996;77:293-301.
60. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al. HIV-1 nomenclature proposal. *Science* 2000;288:55-56.

61. Depla E, Maertens G, De Nys K, Blockx H, van Doorn LJ, Quint W, et al. A putative new clade 7 of Hepatitis C virus containing at least one type and two subtypes. 10th International Meeting on Hepatitis C Virus and Related Viruses, December 2-6, 2003, Kyoto, Japan.
62. Murphy D, Willems B, Deschenes M, Hilzenrat N, Mousseau R. Use of nucleotide sequence analysis of the NS5B region for routine genotyping of hepatitis C virus: identification of numerous variants not classifiable among the known HCV genotypes. *HEPATOLOGY* 2003;38:423A.
63. Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *J Virol* 1996;70:3363-3371.
64. Bulch J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. *Proc Natl Acad Sci U S A* 1994;91:8239-8243.
65. Ray SC, Arthur RR, Carella A, Bulch J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. *J Infect Dis* 2000;182:698-707.
66. Stuyver L, Vanarnhem W, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5b regions and identification of five additional subtypes. *Proc Natl Acad Sci U S A* 1994;91:10134-10138.
67. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci U S A* 1991;88:2451-2455.
68. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. *Proc Natl Acad Sci U S A* 1991;88:10292-10296.
69. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci U S A* 1990;87:9524-9528.
70. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. *J Virol* 1991;65:1105-1113.
71. Okamoto H, Kojima M, Sakamoto M, Iizuka H, Hadiwandowo S, Suwignyo S, et al. The entire nucleotide sequence and classification of a hepatitis C virus isolate of a novel genotype from an Indonesian patient with chronic liver disease. *J Gen Virol* 1994;75:629-635.
72. Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. *J Gen Virol* 1991;72:2697-2704.
73. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. *J Med Virol* 2001;64:334-339.
74. Murakami K, Abe M, Kageyama T, Kamoshita N, Nomoto A. Down-regulation of translation driven by hepatitis C virus internal ribosomal entry site by the 3' untranslated region of RNA. *Arch Virol* 2001;146:729-741.
75. Nakao H, Okamoto H, Tokita H, Inoue T, Iizuka H, Pozzato G, et al. Full-length genomic sequence of a hepatitis C virus genotype 2c isolate (BEBE1) and the 2c-specific PCR primers. *Arch Virol* 1996;141:701-704.
76. Sakamoto M, Akahane Y, Tsuda F, Tanaka T, Woodfield DG, Okamoto H. Entire nucleotide sequence and characterization of a hepatitis C virus of genotype v/3a. *J Gen Virol* 1994;75:1761-1768.
77. Yamada N, Tanihara K, Mizokami M, Ohba K, Takada A, Tsutsumi M, et al. Full-length sequence of the genome of hepatitis C virus type 3a: comparative study with different genotypes. *J Gen Virol* 1994;75:3279-3284.
78. Chayama K, Tsubota A, Koida I, Arase Y, Saitoh S, Ikeda K, et al. Nucleotide sequence of hepatitis C virus (type 3b) isolated from a Japanese patient with chronic hepatitis C. *J Gen Virol* 1994;75:3623-3628.
79. Chamberlain RW, Adams NJ, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. *J Gen Virol* 1997;78:1341-1347.
80. Chamberlain RW, Adams NJ, Taylor LA, Simmonds P, Elliott RM. The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. *Biochem Biophys Res Commun* 1997;236:44-49.
81. Bulch J, Apgar CL, Engle R, Govindarajan S, Hegerich PA, Tellier R, et al. Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. *J Infect Dis* 1998;178:1193-1197.
82. Adams NJ, Chamberlain RW, Taylor LA, Davidson F, Lin CK, Elliott RM, et al. Complete coding sequence of hepatitis C virus genotype 6a. *Biochem Biophys Res Commun* 1997;234:393-396.
83. Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Miyakawa Y, et al. The entire nucleotide sequences of three hepatitis C virus isolates in genetic groups 7-9 and comparison with those in the other eight genetic groups. *J Gen Virol* 1998;79:1847-1857.
84. Stuyver L, Wyseur A, Van Arnhem W, Lunel F, Laurent-Puig P, Pawlotsky JM, et al. Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples. *Virus Res* 1995;38:137-157.
85. Stuyver L, Esquivel C, Boudifa A, Jaulmes D, Azar N, Lunel F, et al. Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive Parisian blood donors. *Transfusion* 1996;36:552-558.
86. Van Doorn LJ, Kleter GEM, Stuyver L, Maertens G, Brouwer JT, Schalm SW, et al. Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries. *J Gen Virol* 1995;76:1871-1876.
87. Stuyver L, Wyseur A, Van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. *J Clin Microbiol* 1996;34:2259-2266.
88. Qu D, Hantz O, Gouy M, Vitvitski L, Li JS, Berby F, et al. Heterogeneity of hepatitis C virus genotypes in France. *J Gen Virol* 1994;75:1063-1070.
89. Giannini C, Thiers V, Nousbaum JB, Stuyver L, Maertens G, Brechot C. Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers or probes. *J Hepatol* 1995;23:246-253.
90. Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK. Genotype determination of hepatitis C virus from Northern India: identification of a new subtype. *J Med Virol* 1996;48:191-198.
91. Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. *J Clin Microbiol* 1996;34:2815-2818.
92. Abid K, Quadri R, Veuthey AL, Hadengue A, Negro F. A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3. *J Gen Virol* 2000;81:1485-1493.
93. Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, Jeantils V, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. *J Gen Virol* 2001;82:1001-1012.
94. Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, Holmes EC, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. *J Gen Virol* 1996;77:3013-3024.
95. Doi H, Apichartpiyakul C, Ohba KI, Mizokami M, Hotta H. Hepatitis C virus (HCV) subtype prevalence in Chiang Mai, Thailand and identification of novel subtypes of HCV in major type 6. *J Clin Microbiol* 1996;34:569-574.
96. Apichartpiyakul C, Chittivudikarn C, Miyajima H, Homma M, Hotta H. Analysis of hepatitis C virus isolates among healthy blood donors and drug addicts in Chiang Mai, Thailand. *J Clin Microbiol* 1994;32:2276-2279.
97. Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. *Bioinformatics* 2001;17:1244-1245.

Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B

Hiroyuki Nakanishi^a Masayuki Kurosaki^a Yasuhiro Asahina^a Yuko Onuki^a
Ken Ueda^a Yuki Nishimura^a Kaoru Tsuchiya^a Takatoshi Kitamura^a
Masakatsu Uchihara^a Shozo Miyake^a Nobuyuki Enomoto^b Namiki Izumi^a

^aDivision of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, and ^bFirst Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan

Key Words

Lamivudine · Breakthrough hepatitis · INNO-LiPA · Hepatitis B virus DNA · Domain B

Abstract

Breakthrough hepatitis remains the major issue in long-term lamivudine therapy for chronic hepatitis B. However, the emergence of drug-resistant hepatitis B virus (HBV) is not always accompanied by a relapse of hepatitis. To elucidate factors predictive of breakthrough hepatitis, 53 patients with genotype C of HBV on long-term lamivudine therapy were analyzed. HBV reappeared during therapy in 19 patients with a cumulative incidence of 15% at 1 year, 34% at 2 years, and 60% at 3 years. Within this group, breakthrough hepatitis developed in 12 patients (63%). A polymerase gene domain B mutation (rt180M) emerged in 13 patients, and domain C mutations (rt204I, rt204V) were found in 19 patients. The rt180M mutation was associated with breakthrough hepatitis ($p < 0.05$) with a positive predictive value of 85% and a negative predictive value of 83%. Patients with the rt180M mutation had higher HBV-DNA levels during viral breakthrough compared to patients with rt180wt ($p < 0.05$). The mutational pattern of rt204 was not associated with breakthrough hepatitis. In conclusion, genotypic assays for the rt180M mutation after viral breakthrough

may be useful in predicting the risk of breakthrough hepatitis and in deciding when to initiate alternative or additive nucleoside analogue therapy.

Copyright © 2005 S. Karger AG, Basel

Introduction

Lamivudine, a nucleoside analogue, is now widely used as primary therapy for chronic hepatitis B virus (HBV) infection [1]. The initial clinical response is usually favorable with high rates of HBV suppression, normalization of serum alanine transaminase (ALT) levels, loss of detectable serum HBe antigen, as well as histologic improvement [2–7]. However, short-term therapy cannot completely eliminate the HBV pool in the liver [8], and cessation of therapy usually leads to withdrawal hepatitis [9–11]. Consequently, long-term therapy is required in the majority of patients to maintain the suppressive effects of lamivudine.

Unfortunately, long-term therapy has drawbacks as well. Response rates may gradually decrease due to the emergence of drug-resistant HBV. This resistant virus form is characterized by amino acid mutations in the catalytic domains of the polymerase gene. Two mutations are frequently observed in association with lamivudine resistance: a mutation of methionine to isoleucine or va-

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2005 S. Karger AG, Basel
0300-5526/05/0486-0381\$22.00/0

Accessible online at:
www.karger.com/int

Namiki Izumi, MD
Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital
1-26-1 Kyonan-cho, Musashino-shi
Tokyo 180-8610 (Japan)
Tel. +81 422 32 3111, Fax +81 422 32 9551, E-Mail nizumi@musashino.jrc.or.jp

line in codon 204 of the catalytic domain C, and a mutation of leucine to methionine in codon 180 of the catalytic domain B [12]. The emergence of these mutations leads to the reappearance of HBV-DNA (viral breakthrough) and the relapse of hepatitis (breakthrough hepatitis) [13] at cumulative rates of 14–32% at 1 year and 38–49% at 2 years [2, 4, 5, 14, 15].

However, biochemical changes do not always correlate with drug resistance. In some cases of viral breakthrough during long-term lamivudine therapy, patient ALT levels remain unaffected, and these patients continue to exhibit histologic improvement [12, 15]. Conversely, there are also patients who develop a severe flare-up of their hepatitis or even frank decompensation when viral resistance emerges [6, 16–20]. The risk of hepatitis B relapse thus becomes an important issue in patients undergoing long-term treatment with lamivudine. While various factors such as pretreatment HBV-DNA levels, ALT levels, presence of HBe antigen, and certain genotypes, may be associated with the emergence of resistant viral strains, factors predictive of a patient's clinical outcome have not yet been defined. Given the wide variability in patient responses to viral breakthrough and the potential morbidity and mortality associated with the worst outcomes, identifying pretreatment factors predictive of breakthrough hepatitis could be very relevant to clinical practice.

Finally, when analyzing treatment resistance, it is also important to consider the HBV viral genotype. Viral genotype may have some bearing on patient outcomes with long-term lamivudine therapy. For example, patients infected with genotype A who develop viral breakthrough while on lamivudine tend to have higher HBV-DNA levels than patients who harbor other HBV genotypes such as D. Investigators have recently shown that the pattern of polymerase gene mutation leading to lamivudine resistance may be different for genotype A [21]. A double mutation of methionine to valine in codon 204 and leucine to methionine in codon 180 was prevalent in genotype A, while a methionine to isoleucine mutation in codon 204 occurred more frequently in genotype D. These differences in mutational patterns may be linked to an association between genotype and HBV-DNA levels after viral breakthrough.

Currently, the most prevalent HBV genotype in Japan is genotype C [22]. Genotype C is reported to be associated with a more aggressive clinical course and increased resistance to interferon therapy when compared to genotype B [23–25]. Given the pertinence of genotype in lamivudine resistance, differentiating the clinical signifi-

cance of the various polymerase gene mutations in genotype C becomes critical.

The aim of the present study is to elucidate factors associated with breakthrough hepatitis during long-term lamivudine therapy in HBV genotype C infections. Mutations in domains B and C of the polymerase gene, core promoter gene and precore gene were analyzed to determine if specific mutational patterns might be associated with different clinical outcomes.

Patients and Methods

Therapeutic Protocol

Fifty-three patients with chronic hepatitis B genotype C who were consecutively started on long-term lamivudine monotherapy between August 1999 and November 2003 at Musashino Red Cross Hospital were analyzed retrospectively. There were 32 males and 21 females; mean age was 48.8 ± 11.8 years. At the start of therapy, all patients had detectable levels of HBV-DNA in their blood by polymerase chain reaction (PCR), as well as elevations in serum ALT levels. All patients were also found not to have either hepatitis C or human immunodeficiency virus antibodies in their blood. No patient received interferon or any other antiviral agents during the study or within 6 months of initiating lamivudine therapy. Patients were treated with a single oral dose of 100 mg of lamivudine every day; median duration of lamivudine therapy was 689 (range 207–1,736) days. All patients remained on lamivudine therapy throughout the course of study except those who developed breakthrough hepatitis. Informed consent was obtained from each patient included in the study and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Quantification of HBV-DNA

Blood samples were obtained at the start of therapy and then once every month during therapy. The serum level of HBV-DNA was determined using transcription-mediated amplification and hybridization protection assays (Fujirebio Inc., Tokyo, Japan) that have a detection range of 3.7–8.7 log genome equivalents (LGE)/ml [26].

Definitions

Viral breakthrough was defined as an elevation of more than 1 LGE/ml of HBV-DNA accompanied by mutations in the polymerase gene on 3 consecutive determinations during monthly testing after a period of HBV-DNA suppression. No case that met this definition experienced a spontaneous decline in HBV-DNA thereafter. Breakthrough hepatitis was defined as a sustained elevation in serum ALT levels on 2 consecutive determinations 2 weeks apart in concert with viral breakthrough.

Analysis of Precore and Core Promoter Mutations

Mutations in the precore and core promoter regions were analyzed at baseline. The A1762T and G1764A mutations in the basic core promoter [27] were detected by a commercially available en-

zyme-linked specific probe assay (Smitest HBV core promoter mutation detection kit, Genome Science Laboratory, Tokyo). The G1896A stop codon mutation in the precore region was detected by an enzyme-linked mini sequence assay (Smitest HBV Pre-C ELMA, Roche Diagnostics, Tokyo). Use of both of these assays has been described previously [28].

Analysis of Lamivudine-Resistant HBV

Blood samples at the time of viral breakthrough were analyzed for mutations in the HBV polymerase associated with lamivudine resistance using INNO-LiPA HBV DR analysis (Innogenetics, Inc., Ghent, Belgium) [29, 30]. Briefly, DNA isolated from the serum was amplified by nested PCR and used for hybridization to the LiPA strips. The probes on the INNO-LiPA HBV DR strip cover the amino acids of codon 180 (wild-type leucine (L) and mutant methionine (M)) and codon 204 (wild-type methionine and mutants valine (V) and isoleucine (I)). The amino acid positions on the HBV polymerase gene are numbered for consistency with the newly established standardization of nomenclature for lamivudine-resistance mutations rtI80M and rt204V/I (originally designated as L528M or L526M and M552V/I or M550V/I) [31].

Statistical Analysis

For statistical analysis the STAT View software package was used. Categorical data were analyzed using Fisher's exact test. Continuous variables were compared with Student's *t* test. A Kaplan-Meier estimate and the log-rank test were used to calculate the median time to and the significance of viral breakthrough, as well as the median time to and the significance of breakthrough hepatitis. Cox's proportional hazard model and stepwise logistic regression analysis were used for multivariate analysis. A *p* value of <0.05 was considered statistically significant.

Results

Patient Characteristics, Pretreatment Variables and Clinical Course

Prior to initiation of lamivudine therapy, the mean HBV-DNA level was 7.1 ± 1.1 LGE/ml, and the mean ALT was 215 ± 285 U/l. Of a total of 53 patients infected with genotype C of HBV, 30 patients had detectable HBeAg in their serum (56.6%). A precore stop codon mutation was detected in 21 patients (42%), and core promoter mutations were detected in 44 patients (88%). The median treatment period was 689 (range 207–1,736) days.

During therapy, detectable levels of HBV-DNA fell below 4 LGE/ml in 42 (79.3%) patients. Viral breakthrough occurred in a total of 19 patients; in these patients, the median time to viral breakthrough was 473 (range 224–1,128) days. The cumulative incidence of viral breakthrough was 15% at 1 year, 34% at 2 years, and 60% at 3 years (fig. 1).





Fig. 1. The cumulative rate of viral breakthrough and breakthrough hepatitis. Kaplan-Meier plot of time to viral breakthrough and time to breakthrough hepatitis in 53 patients treated with lamivudine.

Among those 19 patients who developed viral breakthrough, 12 patients (63%) also developed breakthrough hepatitis. The median time to hepatitis after viral breakthrough was 111 days. The other 7 patients remained in biochemical remission. The cumulative incidence of breakthrough hepatitis was 4% at 1 year, 17% at 2 years, and 45% at 3 years (fig. 1).

Pretreatment variables including age, gender, presence of HBe antigen, HBV-DNA levels, ALT levels, and precore and core promoter mutations were analyzed. These variables were not found to be associated with viral breakthrough or with breakthrough hepatitis (table 1).

Variables at 24 Weeks of Treatment

HBV DNA levels after 24 weeks of lamivudine therapy correlated significantly with eventual viral breakthrough. At week 24 of therapy, HBV-DNA levels were above 4 LGE/ml in 23 patients. Moreover, there was a significant difference in time to viral breakthrough between those whose HBV-DNA levels were above and those whose levels were below 4 LGE/ml after 24 weeks of therapy ($p = 0.007$, Kaplan-Meier log-rank test; fig. 2a). Patients with HBV-DNA levels above 4 LGE/ml had a 3.5-fold higher probability of viral breakthrough compared to the other patients (Cox's proportional hazard model, 95% CI 1.33–9.34, $p = 0.012$). In contrast, the HBV-DNA levels above 4 LGE/ml at week 24 were not associated with breakthrough hepatitis (fig. 2b).



Resistance-Associated Mutations, HBV-DNA Levels after Viral Breakthrough

At the time of viral breakthrough, a polymerase gene mutation in domain B (rt180M) was detected in 13 patients, and a mutation in domain C was detected in 19 patients (rt204I in 10, rt204V in 6 patients and a mixture of rt204I and rt204V in 3 patients). Six patients had a single rt204I mutation; 4 patients had rt180M/rt204I double mutations; 6 patients had rt180M/rt204V double mutations; and 3 patients had rt180M/rt204I/V (mixture) double mutations. The emergence of the rt180M mutation was significantly associated with breakthrough hepatitis: breakthrough hepatitis occurred in 11 of 13 patients with the rt180M mutation, while only 1 of 6 patients with rt180wt (baseline wild-type) developed significant biochemical changes ($p = 0.01$, Fisher's exact test; table 2). The positive predictive value of the presence of rt180M was 85%, and the negative predictive value was

Fig. 2. The cumulative rate of viral breakthrough and breakthrough hepatitis according to HBV-DNA levels after 24 weeks of lamivudine therapy. Patients were divided into 2 groups according to HBV-DNA levels after 24 weeks of lamivudine therapy. Kaplan-Meier plots of time to viral breakthrough (**a**) and time to breakthrough hepatitis (**b**) are shown. Log-rank tests show that higher HBV-DNA levels after 24 weeks of lamivudine therapy are associated with the more rapid development of viral breakthrough ($p = 0.007$) but not with breakthrough hepatitis.

Table 1. Pretreatment variables in association with viral breakthrough and breakthrough hepatitis

	Viral breakthrough		Breakthrough hepatitis	
	no (n = 34)	yes (n = 19)	no (n = 41)	yes (n = 12)
Gender (male/female)	22/12	10/9	16/25	5/7
Age, years	49.8 ± 11.9	47.1 ± 11.8	49.2 ± 11.5	47 ± 13.3
ALT, U/l	255 ± 338	141 ± 128	230 ± 314	159 ± 148
HBeAg positive/negative	17/17	6/13	22/19	8/4
HBV-DNA, LGE/ml	7.0 ± 1.1	7.3 ± 1.1	7.1 ± 1.1	7.2 ± 1.2
CP mutations (M/W)	25/6	19/0	32/6	12/0
PC mutation (M/W)	14/17	7/12	15/23	6/6

HBeAg = Hepatitis Be antigen; CP = core promoter; PC = precore; M = mutant type; W = wild type. There were no variables that had a statistically significant association with viral breakthrough or with breakthrough hepatitis.




Fig. 3. The association between domain B mutations and HBV-DNA levels after viral breakthrough. After viral breakthrough, patients with the rt180M mutation had higher peak levels of HBV-DNA ($p = 0.027$) and larger increases of HBV-DNA ($p = 0.044$) compared to patients with rt180wt.

Table 2. Mutational patterns of the polymerase gene in association with breakthrough hepatitis

Mutational pattern	Breakthrough hepatitis		
	no (n = 7)	yes (n = 12)	p value
rt180M/rt180wt	2/5	11/1	0.01
rt204I/rt204V/rt204V+I	5/2/0	5/4/3	NS
rt204V (yes/no)	2/5	7/5	NS
rt204I (yes/no)	5/2	8/4	NS

NS = Not significant.

83%. Patients with the rt180M mutation had a 27.5-fold higher probability of breakthrough hepatitis compared to those patients with rt180wt (logistic regression analysis, 95% CI 2.00–378.93, $p = 0.013$). In contrast, mutational patterns of rt204 were not associated with breakthrough hepatitis: only 8 of 13 patients with rt240V mutation and 5 of 10 patients with rt240I developed breakthrough hepatitis ($p = 0.35$, Fisher's exact test; table 2).

During viral breakthrough, patients with the rt180M mutation had a larger increase in HBV-DNA levels (3.7 ± 1.2 vs. 2.4 ± 1.2 LGE/ml, $p = 0.044$) and higher peak values of HBV-DNA (7.0 ± 1.3 vs. 5.5 ± 1.2 LGE/ml, $p = 0.027$) compared to those patients with rt180wt (fig. 3).

Discussion

In this study, we found that the rt180M mutation in domain B of the HBV polymerase gene was significantly associated with breakthrough hepatitis during long-term lamivudine therapy in patients with chronic hepatitis B from genotype C. The positive predictive value of this mutation for breakthrough hepatitis was 85%, and the negative predictive value was 83%. The rt180M mutation was always detected as a double mutation with an rt204 mutation. Moreover, it was linked to higher subsequent levels of HBV-DNA during viral breakthrough compared to similar episodes in patients with a single rt204 mutation. Conversely, the mutational patterns of rt204, namely rt204I or rt204V, were not significantly associated with breakthrough hepatitis. Thus, the development of an rt180M mutation in patients on long-term lamivudine therapy might be a useful predictor for breakthrough hepatitis. As such, the presence of this mutation may also be helpful in deciding whether or not to proceed with alternative or additive nucleoside analogues as salvage therapy.

Lamivudine plays an important role in the treatment of patients with chronic hepatitis B. Short-term treatment is insufficient for clearing the virus [8], while long-term treatment is associated with the development of drug-resistant HBV. These strains of drug-resistant HBV do not always precipitate a relapse of hepatitis [12, 15], but the mechanism and predictive factors for the differing clinical outcomes have not been identified.

Previous studies examined factors such as genotype [21], ALT levels [32–34], HBV-DNA levels prior to therapy [21, 33–35], the degree of decline in HBV-DNA levels during therapy [17, 36, 37], the presence of HBeAg [32, 35, 38], and the presence of core promoter mutations [39]. While all of these factors have been found to be related to the appearance of resistant virus strains, the data are inconsistent, and the ultimate role of these factors remains controversial [36]. Moreover, how these and other factors are related to different clinical outcomes after the reappearance of HBV has not been elucidated. This study attempts to identify those predictive factors for break-

through hepatitis during long-term lamivudine therapy that may have an important impact on clinical outcomes.

We found that pretreatment variables, such as mutations in the core promoter and precore genes, HBV DNA levels, ALT levels, and the presence of HBe antigen, were not associated with viral breakthrough or with breakthrough hepatitis. This finding leads us to believe that identifying high-risk patients prior to initiating lamivudine therapy may not be possible. All cases with breakthrough had mutation in the core promoter, but the difference did not reach statistical significance possibly due to the small number of patients with the wild-type sequence in the core promoter. Further study including a larger number of patients with the wild-type sequence in core promoter may be necessary to elucidate the significance of the mutation in the core promoter in breakthrough.

However, when patients were analyzed after 24 weeks of lamivudine therapy, we found that HBV-DNA levels were significantly associated with the development of viral breakthrough, a finding consistent with previous reports [17, 36, 37]. Additionally, higher rates of spontaneous mutations in the viral genome are likely to be associated with higher replication levels [40], leading to the emergence of resistant HBV. Given these findings, monitoring for HBV-DNA levels at 24 weeks may be useful in targeting patients at higher risk for viral breakthrough but not necessarily for breakthrough hepatitis.

When parameters at the time of viral breakthrough were analyzed, the rt180M mutation was significantly associated with the occurrence of breakthrough hepatitis. Among those we studied the rt180M was the sole marker that was associated with breakthrough hepatitis, therefore close monitoring and detection of this mutation may be useful clinically in the prediction of breakthrough hepatitis.

The mechanism underlying the association of rt180M mutation with breakthrough hepatitis is not well understood. Usually, the rt204V/I mutant virus is less efficient at replication than the rt204wt virus. However, in tissue culture, the mutants with both B and C domain mutations (rt180M and rt204I/V) have higher reverse transcriptase activity and replication capacity than those single C-domain mutants (rt180wt and rt204I/V). Domain C rt204 is located in the conserved YMDD motif of the RNA-dependent RNA polymerase and is involved in nucleotide binding [41], while domain B is involved in template positioning [42]. Since these two domains interact in the molecular model of HBV reverse transcriptase [43], it

might be speculated that the rt180M mutation interacts with the rt204 mutations. In essence, in double mutants, the B-domain mutation rt180M may compensate for the replication defective C-domain mutants [44], thus accounting for the higher reverse transcriptase activity and replication capacity compared to single C-domain mutants. These *in vitro* findings are consistent with our findings that patients with both B and C domain mutants were associated with higher HBV-DNA levels during viral breakthrough than those with single C-domain mutants. It has also been suggested that cellular immune responsiveness to HBV may increase after suppression of viremia when using antiviral therapy such as lamivudine [45]. Thus, when viral breakthrough occurs in patients whose cellular immunity has been relatively restored, a relapse of hepatitis may occur. Additionally, the amino acid position 180 may be a more vulnerable target to the restored immune system, a possibility that needs to be examined by further study.

In conclusion, the results of this study offer potentially important clinical ramifications for patients infected with genotype C hepatitis B who are on long-term lamivudine therapy. The quantification of HBV viremia after 24 weeks of lamivudine therapy may predict patients who are at a higher risk for viral breakthrough. Closer monitoring may thus be warranted in those patients with HBV-DNA levels of >4 LGE/ml. When viral breakthrough does occur, genotypic assays for the rt180M mutation should be performed since this mutation may be predictive of hepatitis relapse.

It is our belief that using both a quantitative assay for HBV viremia at 24 weeks and genotypic assays for polymerase mutant detection after viral breakthrough may serve as an effective means of monitoring long-term lamivudine therapy in chronic hepatitis B genotype C patients. Together, the results from these assays can provide useful information that may influence the decision to initiate early induction of salvage therapy.

References

- ▶ 1 Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000 – Summary of a workshop. *Gastroenterology* 2001;120:1828–1853.
- ▶ 2 Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. *Asia Hepatitis Lamivudine Study Group. N Engl J Med* 1998;339:61–68.
- ▶ 3 Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. *J Hepatol* 1999;30:743–748.
- ▶ 4 Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999;341:1256–1263.
- ▶ 5 Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. *Asia Hepatitis Lamivudine Study Group. Gastroenterology* 2000;119:172–180.
- ▶ 6 Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condey LD, Chien RN: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. *Hepatology* 2001;33:1527–1532.
- ▶ 7 Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H: Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. *Intervirology* 2003;46:164–170.
- ▶ 8 Moraleda G, Saputelli J, Aldrich CE, Averett D, Condey L, Mason WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. *J Virol* 1997;71:9392–9399.
- ▶ 9 Honkoop P, de Man RA, Niesters HG, Zonder van PE, Schalm SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. *Hepatology* 2000;32:635–639.
- ▶ 10 Chien RN, Liaw YF: Short-term lamivudine therapy in patients with chronic hepatitis B. *Intervirology* 2003;46:362–366.
- ▶ 11 Yotsuyanagi H, Yasuda K, Iino S: Short-term lamivudine for the treatment of chronic hepatitis B. *Intervirology* 2003;46:367–372.
- ▶ 12 Lok AS, McMahon BJ: Chronic hepatitis B: Update of recommendations. *Hepatology* 2004;39:857–861.
- ▶ 13 Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. *Hepatology* 1998;27:1711–1716.
- ▶ 14 Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. *Gut* 2000;46:562–568.
- ▶ 15 Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condey LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. *Hepatology* 2000;32:828–834.
- ▶ 16 Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS: Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. *Hepatology* 2001;34:583–589.
- ▶ 17 Zollner B, Schafer P, Feucht HH, Schroter M, Petersen J, Laufs R: Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. *J Med Virol* 2001;65:659–663.
- ▶ 18 Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. *Hepatology* 1999;30:567–572.
- ▶ 19 Honkoop P, de Man RA, Niesters HG, Schalm SW: Clinical impact of lamivudine resistance in chronic hepatitis B. *J Hepatol* 1998;29:510–511.
- ▶ 20 Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY: Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. *Clin Infect Dis* 2001;33:403–405.
- ▶ 21 Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayer J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH: Viral features of lamivudine resistant hepatitis B genotypes A and D. *Hepatology* 2004;39:42–50.
- ▶ 22 Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001;34:590–594.
- ▶ 23 Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000;118:554–559.
- ▶ 24 Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S: A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. *Japan HBV Genotype Research Group. Hepatology* 2001;33:218–223.
- ▶ 25 Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003;37:19–26.
- ▶ 26 Sakugawa H, Kobashigawa K, Nakayoshi T, Yamashiro T, Maeshiro T, Tomimori K, Kinjo F, Saito A, Mukaide M: Monitoring low level hepatitis B virus by a newly developed sensitive test. *Hepatol Res* 2003;26:281–286.
- ▶ 27 Kurosaki M, Enomoto N, Asahina Y, Sakuma I, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C: Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. *J Med Virol* 1996;49:115–123.
- ▶ 28 Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S: Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. *J Hepatol* 2003;39:1063–1069.
- ▶ 29 Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R: Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. *J Clin Microbiol* 2000;38:702–707.
- ▶ 30 Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E: Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. *J Clin Microbiol* 2002;40:3729–3734.
- ▶ 31 Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. *Hepatology* 2001;33:751–757.
- ▶ 32 Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. *Hepatology* 2000;32:1078–1088.
- ▶ 33 Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. *Hepatology* 2001;34:785–791.
- ▶ 34 Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R: Genotypic and phenotypic resistance: Longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. *Am J Gastroenterol* 2003;98:151–159.

- ▶ 35 Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Matsuda M, Satoh J, Takagi K, Kumada H: Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 2003;46:182-189.
- ▶ 36 Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B: Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. *Hepatology* 2004;39:64-73.
- ▶ 37 Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H: Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. *J Infect Dis* 2000;181:2063-2066.
- ▶ 38 Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Saitoh S, Arase Y, Ikeda K, Kumada H: The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. *J Hepatol* 2003;38:315-321.
- ▶ 39 Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P: Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. *Hepatology* 2000;32:1145-1153.
- ▶ 40 Gunther S, Fischer L, Pult I, Sterneck M, Will H: Naturally occurring variants of hepatitis B virus. *Adv Virus Res* 1999;52:25-137.
- ▶ 41 Poch O, Sauvaget I, Delarue M, Tordo N: Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. *EMBO J* 1989;8:3867-3874.
- ▶ 42 Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, et al: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. *Proc Natl Acad Sci USA* 1993;90:6320-6324.
- ▶ 43 Allen MI, Deslauriers M, Andrews CW, Tipple GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. *Lamivudine Clinical Investigation Group. Hepatology* 1998;27:1670-1677.
- ▶ 44 Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. *J Clin Invest* 2001;107:449-455.
- ▶ 45 Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. *J Clin Invest* 1998;102:968-975.

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C[☆]

Yasuhiro Asahina¹, Namiki Izumi^{1,*}, Nobuyuki Enomoto², Masakatsu Uchihara¹,
Masayuki Kurosaki¹, Yuko Onuki¹, Yuki Nishimura¹, Ken Ueda¹, Kaoru Tsuchiya¹,
Hiroyuki Nakanishi¹, Takatoshi Kitamura^{1,2}, Shozo Miyake¹

¹Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan

²First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110 Shimogato, Tamaho-cho, Nakakoma-gun, Yamanashi 409-3898, Japan

See Editorial, pages 553–555

Background/Aims: To elucidate whether ribavirin acts as a mutagen in the clinical setting and to clarify the relationship between ribavirin-induced mutations and virological response to combined therapy.

Methods: Thirty-four patients with hepatitis C virus (HCV) genotype 1b received ribavirin monotherapy for 4 weeks, followed by a 24-week course of IFN/ribavirin therapy. HCV mutations during a non-treatment observation period and during subsequent ribavirin monotherapy were determined, and the relationship between mutations and response to subsequent IFN/ribavirin therapy was evaluated.

Results: Serum HCV significantly decreased from 6.90 to 6.56 log₁₀copy/ml in response to ribavirin monotherapy ($P < 0.0001$). Nucleotide mutations in the NS5A and NS5B regions occurred during ribavirin monotherapy at a rate of 2.9×10^{-2} /site/year and 1.3×10^{-2} /site/year, respectively, a significantly higher rate than the mutation rates during the prior non-treatment observation period (0.60×10^{-2} /site/year and 0.24×10^{-2} /site/year, $P = 0.02$, respectively). Mutation rates in the NS5A region were significantly higher in sustained viral responders (SVRs, $n = 10$) than in non-responders (8.8×10^{-2} /site/year vs. 0.38×10^{-2} /site/year, $P = 0.0005$, respectively). In the NS5A region, non-synonymous mutations only occurred in SVRs.

Conclusions: Ribavirin may act as a mutagen, and mutations occurring during ribavirin therapy correlate with the virological response to subsequent IFN/ribavirin combination therapy.

© 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords: NS5A; NS5B; ISDR; HCV; HCV dynamics

Received 31 January 2005; received in revised form 16 April 2005; accepted 3 May 2005; available online 1 July 2005

[☆] The authors who have taken part in this study declared that they have not a relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out their research. The nucleotide sequences reported in this paper will appear in the DDBJ/EMBL/GenBank with accession numbers AB207766 through AB207801.

* Corresponding author. Tel.: +81 422 32 3111; fax: +81 422 32 9551.

E-mail address: nizumi@musashino.jrc.or.jp (N. Izumi).

Abbreviations: HCV, hepatitis C virus; IFN, interferon; RdRp, RNA dependent RNA polymerase; PCR, polymerase chain reaction; SVR, sustained viral responder; NR, non-responder; ISDR, interferon sensitivity determining region.

0168-8278/\$30.00 © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.jhep.2005.05.032

1. Introduction

Ribavirin, a synthetic guanosine analog, has broad antiviral effects against both DNA and RNA viruses. Although ribavirin monotherapy has minimal efficacy on hepatitis C viral (HCV) eradication [1–3], studies have reported higher sustained response rates following combination therapy with interferon (IFN)- α and ribavirin than following IFN- α monotherapy [4–7]. Several mechanisms of action of ribavirin have been proposed [8]. In vitro and animal studies, in particular, have demonstrated that the antiviral activity of ribavirin is exerted through its potent mutagenic effects on RNA viruses after being incorporated into newly synthesized genomes by viral RNA-dependent RNA polymerase (RdRp) [9–11]. Still, little information is available regarding the mechanisms responsible for the increased virological efficacy associated with concurrent administration of ribavirin and IFN. No clinical studies to date have determined whether ribavirin induces mutations in the clinical setting nor examined the relationship between the mutagenic effects of ribavirin and viral response to IFN/ribavirin combination therapy.

The present study evaluated a set of patients with chronic hepatitis C. To elucidate whether ribavirin acts as a mutagen in the clinical setting, for each subject the sequential nucleotide mutations occurring during ribavirin monotherapy were compared with mutations occurring in the same patient during the non-treatment observation period immediately preceding the initiation of ribavirin monotherapy as a control. The relationship between mutations observed during ribavirin monotherapy and viral response to subsequent IFN/ribavirin combination therapy was also determined.

2. Methods

2.1. Patients

Among patients with biopsy-proven chronic hepatitis C hospitalized at the Musashino Red Cross Hospital from December 2001 to June 2002, 34 patients of HCV genotype 1b with a high viral load (>100 kcopies/ml by Amplicor-HCV monitor assay; Roche Molecular Diag. Co., Tokyo, Japan) were included in the present study (Table 1). Patients with liver cirrhosis, autoimmune hepatitis, and alcoholic liver injury were excluded from the study. No patient was positive for hepatitis B virus-associated antigen/antibody or anti-human immunodeficiency virus antibody. No patient received immunomodulatory therapy before enrolment in the study. Written informed consent was obtained from all patients, and this study was approved by the ethical committee of Musashino Red Cross Hospital in accordance with the Helsinki Declaration.

2.2. Treatment protocol and study design

Treatment schedule and time points for sequential genetic analysis are described in the upper part of Fig. 1. Following a non-treatment observation period, all patients received oral ribavirin daily for 4 weeks. Ribavirin dosage was 600 mg daily for patients who weighed less than 60 kg and 800 mg daily for patients who weighed between 60 and 80 kg. All patients subsequently received a 24-week course of treatment consisting of

Table 1
Clinical characteristics of the study patients

No. of patients	34
Age (years)	59 \pm 8
Gender (M/F)	14/20
Liver histology	
A1/A2/A3	14/15/5
F1/F2/F3	10/15/9
Number of ISDR mutations (0/1)	22/12
Baseline data	
ALT (IU/L)	81 \pm 56
Platelet count ($\times 10^3$ /ml)	150 \pm 52
Viral load (KIU/ml)	572 \pm 204
SVR (%)	29.4 (10/34)

Values are expressed as mean \pm standard deviation.

intramuscular IFN- α 2b (Intron, Schering-Plough, Kenilworth, NJ) at an initial dosage of 6 MU daily in combination plus daily oral ribavirin at the same dosage (600 mg daily or 800 mg daily) as was given during pretreatment monotherapy. After the first 2 weeks of IFN/ribavirin combination therapy, the IFN dosing frequency was reduced to 6 MU three times a week for the remaining 22 weeks.

Nucleotide sequences of the NS5A and NS5B regions of the HCV genome were determined at the following time points: (1) enrolment into the study; (2) end of the non-treatment observation period (immediately before initiation of ribavirin monotherapy); (3) end of the 4-week ribavirin monotherapy (immediately before initiation of IFN/ribavirin combination therapy). For each patient, nucleotide changes between time points 1 and 2 during the non-treatment observation period (mean: 6 months, range: 2–48 months) were used as a control to determine whether mutations observed during the period of ribavirin monotherapy (between time points 2 and 3) represented true effects of ribavirin. Mutation rates for the non-treatment observation period were compared with the mutation rates during the subsequent ribavirin monotherapy period. Moreover, the relationships between observed mutations and the clinical outcome of the subsequent IFN/ribavirin therapy were evaluated.

2.3. Nucleotide sequencing

Nucleotide sequences of the NS5A and NS5B regions of the HCV genome were determined by direct sequencing of polymerase chain reaction (PCR)-amplified DNA, as previously described [12,13]. In brief, after RNA was extracted from sera of the study subjects, NS5A and NS5B regions were amplified by RT-PCR using Taq polymerase, and the sequences corresponding to nucleotides 6703–7320 and 7730–8874 of HCV-J were determined [13]. The sequences of the primers for the NS5A region were the same as described previously [12]. Sequences for the NS5B region, which were amplified with two partially overlapping sets of primers, were as follows: NS5B1-5' outer set, 5'GGTGAATACCTGGAAATCA-AAGAAA3'; NS5B1-3' outer set, 5'AGAAATGAGTCATCAGAATCAT-CCT3'; NS5B1-5' inner set, 5'TGTAACACGACGCCAGTATGGGCT TCTCATATGACAC3'; NS5B1-3' inner set, 5'CAGGAAACAGCTAT-GACCCATGATGATGTTGCCATGCC3'; NS5B2-5' outer set, 5'GCA-GAAGAAGGTCACCTTGACAGA3'; NS5B2-3' outer set, 5'TCGGG GGCCAAGTCACAACATTGGT3'; NS5B2-5' inner set, 5'TGTAACAA-GCACGGCCAGTTTTCAGACAGACTGCAAGTCCT3'; NS5B2-3' inner set, 5'CAGG AACAGCTATGACCTTCTCAGTGACCGTTGAGTC3'. M13-forward and M13-reverse sequences were attached to the 5'-termini of sense and anti-sense nested PCR primers. Both strands of the PCR products were cycle sequenced with the PRISM dye termination kit (CN402069, Applied Biosystems, Chiba, Japan), and nucleotide sequences were determined by an automated DNA sequencer Model 373A (Applied Biosystems).

Mutations resulting from ribavirin therapy were defined as the detection of a new nucleotide which was not detected as even a minority population in the prior specimen from that subject. Electropherograms were read by two independent readers without knowledge of the patients' backgrounds and outcomes. A nucleotide detected in the post-ribavirin monotherapy specimen was considered to be a 'new nucleotide' only when both readers could not identify any tracking peak of this nucleotide in a prior specimen.




Fig. 1. Treatment schedule and HCV dynamics during ribavirin monotherapy and subsequent IFN/ribavirin combination therapy. After a non-treatment observation period, all patients received oral ribavirin daily for 4 weeks and subsequently received intramuscular IFN- α 2b in combination with daily oral ribavirin. For the first 2 weeks of IFN/ribavirin combination therapy, 6 MU of IFN- α 2b was given daily; the IFN dosing frequency was then reduced to 6 MU three times a week for the remaining 22 weeks of combination therapy. Serum HCV dynamics of individual patients are shown in dotted lines, and the solid line represents the mean of these values. The nucleotide sequences were serially analyzed at the time points indicated by the arrows. Closed triangles indicate the time points of serum ribavirin concentration measurements.

Peaks less than 10% of the dominant peak were considered to be background signals. To calculate values for dN (nonsynonymous substitution), dS (synonymous substitution), dN/dS ratios, and the number of point mutations, analyses of nucleotide sequences were performed using a software program (MEGA version 2.1.). Separate dN/dS ratios were determined for each NS5 region in patients who had nucleotide mutations in the corresponding NS5 regions. To determine the locations of amino acid mutations in the tertiary structure of the NSSB molecule, a crystal structure model of HCV NSSB-RdRp was constructed using 1QUV from the Protein Data Bank. A space-filling representation of each atom was generated using RasMol 2.7.2.1. The deduced amino acid sequences of the NS5A and NS5B regions were also compared with a prototype HCV 1b strain, HCV-J [14].

2.4. HCV dynamics in serum

To analyze the effect of ribavirin on viral dynamics, HCV-RNA concentrations were quantified just before and at the end of ribavirin monotherapy, and also at 4, 8, 24, 48, 96, 192, and 336 hours after initiating IFN/ribavirin combination therapy, using real-time detection PCR, as reported previously [15–17]. The detection sensitivity of this assay is approximately 10 copies/ml, and the dynamic range is from 10 copies/ml to more than 1×10^8 copies/ml [17]. For each patient, the viral decline curve was plotted on a semilogarithmic scale, and the slopes of the exponential viral declines were calculated for each viral decline phase by a straight-line fit of the data.

2.5. Definitions of response to therapy

A patient negative for serum HCV-RNA during the first six months following the completion of IFN/ribavirin combination therapy was defined as a sustained viral responder (SVR), and a patient positive for HCV-RNA during this time period was defined as a non-responder (NR).

2.6. Statistical analysis

Categorical data were compared by the chi-square test or Fisher's exact test. Distributions of continuous variables were analyzed by the Student's

t -test for two groups. All tests of significance were two-tailed, and P values less than 0.05 were considered statistically significant.

3. Results

3.1. HCV dynamics

During the 4-week period of ribavirin monotherapy, the mean serum HCV-RNA level significantly decreased from 6.90 to 6.56 \log_{10} copy/ml ($P < 0.0001$, paired t test) (Fig. 1). Serum HCV dynamics after the start of subsequent IFN/ribavirin combination therapy demonstrated a biphasic kinetic pattern of HCV-RNA decline. The exponential decay slopes for the first phase and the second phase were $2.00 \pm 0.77 \log_{10}/\text{day}$ and $0.15 \pm 0.14 \log_{10}/\text{day}$, respectively.

3.2. The effect of ribavirin on HCV gene mutation and the relationship between mutations and virological response to IFN/ribavirin combination therapy

In a pairwise comparison of the NS5 sequences before and after ribavirin monotherapy, new HCV gene mutations occurring during ribavirin monotherapy were observed in the NS5A region in 10 patients and in the NS5B region in 8 patients. Mean gene mutation rates in the NS5A and NS5B regions during ribavirin administration were $2.9 \times 10^{-2}/\text{site/year}$ and $1.3 \times 10^{-2}/\text{site/year}$, respectively, rates which were significantly higher compared with the rates observed during the prior non-treatment observation periods in

Table 2
Mutation rates during the non-treatment observation period and during subsequent ribavirin monotherapy

	NS5A	NS5B
During non-treatment observation period		
Total	0.6×10^{-2}	0.24×10^{-2}
SVR	1.4×10^{-2}	0.46×10^{-2}
NR	0.28×10^{-2}	0.14×10^{-2}
During subsequent ribavirin monotherapy		
Total	2.9×10^{-2}	1.3×10^{-2}
SVR	8.8×10^{-2}	2.2×10^{-2}
NR	0.38×10^{-2}	0.96×10^{-2}

Note that the difference in NS5A mutation rate between SVR and NR patients was greater during ribavirin treatment than that during the non-treatment observation (control) period (23-fold vs. 5-fold). * $P=0.02$ (paired *t* test). † $P=0.02$ (paired *t* test). ‡ $P=0.04$ (unpaired *t* test). § $P=0.0005$ (unpaired *t* test).

the same patients (Table 2, $P=0.02$ for both NS5 regions). Of all nucleotide mutations, 72.1% in the NS5A region and 85.5% in the NS5B region were transition mutations. Percentages of transition mutations for all mutations are detailed in Table 3. Mutations from C to T and from G to A were frequent (Table 3). Synonymous mutations occurred more frequently than non-synonymous mutations in both regions, comprising 80.6% of all NS5A mutations and 73.5% of all NS5B mutations. No significant correlation was found between gene mutation rates and the subject's serum ribavirin concentration at the end of four weeks of ribavirin monotherapy.

Next, the relationship between mutations during ribavirin therapy and virological response to combination therapy was evaluated. The sustained viral response rate was 24.9% (10/34) (Table 1). The proportion of patients who had mutations in

Table 3
Transition mutations during the non-treatment observation period and during subsequent ribavirin monotherapy

	C to T	T to C	G to A	A to G	Others ^a
During non-treatment observation period					
NS5A (%)	22.2	33.3	22.2	11.1	11.2
NS5B (%)	28.5	57.1	0	14.3	0
During subsequent ribavirin monotherapy					
NS5A (%)	18.6	9.3	25.6	18.6	27.9
NS5B (%)	38.5	20.5	10.2	16.3	14.5

Data are expressed as a percentage of all mutations observed in each region.

^a Transversion mutations were included in this column.

the NS5A region during ribavirin monotherapy was significantly higher in SVRs than in NRs (8 out of 10 vs. 2 out of 24 patients, respectively, $P<0.0001$, Fisher's exact test). Correspondingly, gene mutation rates in the NS5A region were significantly higher in SVRs than in NRs: 8.8×10^{-2} /site/year vs. 0.38×10^{-2} /site/year, respectively ($P=0.0005$) (Table 2). In the NS5B region, although statistically significant differences were not observed, the gene mutation rate tended to be higher in SVRs than in NRs: 2.2×10^{-2} /site/year vs. 0.96×10^{-2} /site/year, respectively (Table 2). The proportion of patients with mutations in the NS5B region did not significantly differ between SVRs and NRs.

3.3. Non-synonymous mutations and virological response to IFN/ribavirin combination therapy

In the NS5A region, non-synonymous mutations were found in 19.4% of all nucleotide mutations observed during ribavirin monotherapy. Alterations in deduced amino acid residues by non-synonymous mutations are illustrated in Fig. 2, which shows all 10 patients who had nucleotide mutations during ribavirin monotherapy. In a pairwise comparison between pre- and post-ribavirin monotherapy, amino acid alterations were found in 5 of these 10 patients. Non-synonymous mutations were found exclusively in SVRs. In other words, 5 out of the 8 patients who achieved SVR status had 1 or 3 non-synonymous mutations; 2 of these 5 patients had amino acid alterations accompanied with an increase in the number of amino acid mutations in the interferon sensitivity determining region (ISDR). In contrast, all nucleotide mutations detected in NRs were synonymous mutations. dN/dS tended to be higher in SVRs than in NRs ($P=0.25$, Fig. 3).

In the NS5B region, non-synonymous mutations were detected in 3 out of the 10 SVRs and in 2 out of the 24 NRs. The proportion of patients with non-synonymous mutations did not significantly differ between the two response groups. dN/dS also did not significantly differ between the SVRs and the NRs ($P=0.77$, Fig. 3). Of the 9 amino acid mutations detected in the NS5B region, two were located in the functional domain of the RdRp, one was located in domain C (D310N), and one was located in domain D (R345S). As shown by the crystal model of the NS5B-RdRp in Fig. 4, amino acid mutations were primarily located on the molecular surface; none occurred in the nucleotide groove or in the tunnel.

3.4. Genetic changes during the non-treatment observation period

Gene mutation rates in the NS5A and NS5B regions during the non-treatment observation period were calculated as 0.60×10^{-2} /site/year and 0.24×10^{-2} /site/year, respectively, rates which were significantly lower than the mutation rates observed during ribavirin monotherapy (Table 2). Next, the relationships between viral mutation rates during




Fig. 2. Amino acid sequence alignments in the NS5A region obtained pre- and post-ribavirin monotherapy. The figure contains data for all 10 patients out of 34 with nucleotide mutations occurring during ribavirin monotherapy. Amino acid residues are indicated by the standard single-letter codes, and dashes indicate identical amino acid residues, with the consensus sequence and HCV-J shown at the top. Outcomes of combination therapy are shown on the right side. In a pairwise comparison between pre- and post-ribavirin monotherapy sera, amino acid alterations were found in 5 of 10 patients. Non-synonymous mutations were exclusively found in SVR patients.

the non-treatment observation period and viral responses to subsequent IFN/ribavirin therapy were evaluated. Interestingly, gene mutation rates in the NS5A region during the non-treatment observation period were significantly higher in SVRs than in NRs: 1.4×10^{-2} /site/year vs. 0.28×10^{-2} /site/year, respectively ($P=0.04$). However, it should be noted that the relative difference in NS5A mutation rates between SVRs and NRs during ribavirin treatment was larger than the relative difference between SVRs and NRs during the non-treatment observation period (23-fold vs. 5-fold, $P=0.01$).

Similarly, gene mutation rates in the NS5B region were higher in SVRs (0.46×10^{-2} /site/year) than in NRs (0.14×10^{-2} /site/year), although these differences were not statistically significant. Seven of the nine patients who had mutations occurring during the non-treatment observation period also had mutations during ribavirin monotherapy. However, 53% (8/15) of the patients with mutations during ribavirin monotherapy had no gene mutations during the non-treatment observation period.

4. Discussion

In the present study, we identified HCV gene mutations occurring during ribavirin monotherapy and found that the mutation rate was associated with the virological response to subsequent IFN/ribavirin combination therapy. Since the mutation rate was significantly higher during ribavirin monotherapy than during non-treatment observation periods

in the same patients, at least some of the mutations observed during ribavirin treatment were likely an effect of ribavirin administration. Therefore, ribavirin appears to act as a mutagen during clinical treatment, and this mutagenic effect correlates with improvements in the virological response rate resulting from the synergistic use of ribavirin with IFN.

Recently, several in vitro and animal studies [9–11, 18,19] have provided evidence that ribavirin has mutagenic




Fig. 3. Ratio of *dN* (nonsynonymous substitution) to *dS* (synonymous substitution) distances for the NS5A and NS5B regions. All 10 patients with nucleotide mutations in the NS5A region and all 8 patients with nucleotide mutations in the NS5B region during ribavirin monotherapy are shown in this figure. All pairwise *dN/dS* ratios were calculated using MEGA ver. 2.1 for each subject. *dN/dS* in the NS5A region tended to be higher in SVR patients than in NR patients (NS5A: $P=0.25$, NS5B: $P=0.77$).




Fig. 4. Crystal structure of HCV NS5B-RNA dependent RNA polymerase. The molecular model of NS5B was constructed using 1QUV from the Protein Data Bank. A space-filling representation of each atom is shown. Graphics were generated using Rasmol 2.7.2.1. View of a cross section of the RdRp at level of nucleotide tunnels (A) and the surface (B) are illustrated. Single stranded HCV RNA enters the enzyme through a groove at the top of the finger domain, and NTP (or ribavirin triphosphate; RTP) enters the enzyme through the right lower NTP tunnel (between the fingers and the thumb). The substitutions observed in SVR patients only, NR patients only, and both sets of patients are shown in red, blue, and magenta, respectively.

activity. Other studies have found that ribavirin increases the mutation rate in a full-length HCV cDNA plasmid [20] and in an HCV replicon [21]. However, none of these studies were human studies; no study to date has documented that ribavirin has mutagenic activity in the clinical setting. In the absence of clinical data, the association between the mutagenic activity of ribavirin and the clinical and virological responses to IFN/ribavirin combination therapy remains unknown. Detecting gene mutations induced by ribavirin and analyzing their association with clinical responses to IFN/ribavirin therapy are extremely difficult because HCV with error mutations may be immediately eliminated by the concurrently administered IFN. Although issues regarding the mutagenic effects of ribavirin remain controversial, the inclusion of four weeks of ribavirin monotherapy immediately before

IFN/ribavirin combination therapy in our protocol enabled us to clarify the association between gene mutations induced by ribavirin and the ensuing virological response to the subsequent IFN/ribavirin therapy.

Interestingly, the correlation between mutation rate and virological response to therapy was more evident in the NS5A region, including the ISDR, than in the NS5B region. From our previous analysis of the full-length HCV genome [13,22], NS5A sequences were more variable than NS5B sequences among different clones. Therefore, it seems likely that the stronger relationship observed between mutation rates in the NS5A region and SVR status was due to the relatively greater inherent variability of the NS5A region compared with the NS5B region. Even in the NS5A region, however, serial amino acid mutations rarely occur in the same patients during untreated periods [23]. Hence, our ribavirin monotherapy results suggest that in some patients, ribavirin induces non-synonymous mutations which increase sensitivity to IFN. In turn, this increased susceptibility to IFN could lead to SVR status. Conversely, no functionally important mutations were detected in the NS5B region. Since a ribavirin-induced non-synonymous mutation at a functionally important site in the NS5B region is likely to lead to viral death, even without concurrent IFN administration, the substitutions observed in this critical region are more probably the results of positive or negative selection.

The patients who had gene mutations during the non-treatment observation period were prone to also having mutations during ribavirin monotherapy as well and were more likely to achieve SVR status. These correlations suggest that ribavirin easily induced HCV mutations in such patients. Although mutations could have occurred in the absence of ribavirin, the difference in mutation rates between SVRs and NRs was significantly larger during ribavirin treatment than during the non-treatment observation period (23-fold vs. 5-fold, $P=0.01$). The observation that in more than half of the patients, mutations occurred only during ribavirin monotherapy and were not detectable during the non-treatment observation period suggests that mutagenic effects of ribavirin synergistically potentiating the virological response to IFN may play an important role in achieving SVR status.

Gene mutations in the NS5A and/or NS5B regions during ribavirin monotherapy did not occur in all patients in the present study, suggesting that the intensity of the mutagenic effects of ribavirin differed among individual patients. Additionally, some patients who did not have gene mutations in these regions during the non-treatment observation period or during ribavirin monotherapy nonetheless still achieved SVR, suggesting that the synergistic efficacy of ribavirin may not result solely from the mutagenic activity of this agent. Alternatively, ribavirin may have possibly induced mutations during the period of IFN/ribavirin combination therapy in these patients, but as previously discussed, the concurrent IFN might have eliminated the HCV containing